Jeet Mukherjee
Stock Analyst at BTIG
(4.38)
# 245
Out of 5,090 analysts
14
Total ratings
69.23%
Success rate
17.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeet Mukherjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $167 | $100.49 | +66.19% | 1 | Dec 5, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Buy | $26 | $13.56 | +91.74% | 1 | Nov 7, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Buy | $27 | $18.09 | +49.25% | 3 | Nov 4, 2025 | |
| ARVN Arvinas | Maintains: Buy | $10 → $14 | $12.79 | +9.46% | 2 | Oct 30, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $59 → $75 | $66.62 | +12.58% | 2 | Oct 22, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Buy | $14 | $2.40 | +483.33% | 2 | Oct 13, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $87 → $104 | $80.38 | +29.39% | 3 | Sep 25, 2025 |
Palvella Therapeutics
Dec 5, 2025
Initiates: Buy
Price Target: $167
Current: $100.49
Upside: +66.19%
Aardvark Therapeutics
Nov 7, 2025
Initiates: Buy
Price Target: $26
Current: $13.56
Upside: +91.74%
Nurix Therapeutics
Nov 4, 2025
Reiterates: Buy
Price Target: $27
Current: $18.09
Upside: +49.25%
Arvinas
Oct 30, 2025
Maintains: Buy
Price Target: $10 → $14
Current: $12.79
Upside: +9.46%
Kymera Therapeutics
Oct 22, 2025
Maintains: Buy
Price Target: $59 → $75
Current: $66.62
Upside: +12.58%
Perspective Therapeutics
Oct 13, 2025
Reiterates: Buy
Price Target: $14
Current: $2.40
Upside: +483.33%
Monopar Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $87 → $104
Current: $80.38
Upside: +29.39%